← Leaderboards
Scott James Myers
Neurop, Inc.
$4,164,217
Attributed
$6,373,794
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2006–21$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$6,373,794 · 6
By mechanism
U44$3,507,824 · 1
R44$1,403,583 · 1
R43$817,780 · 2
R21$425,269 · 1
R41$219,338 · 1
Top collaborators
- George Walter Koszalka8 shared
- Kamalesh Ruppa2 shared
- Jon W. Johnson1 shared
Most similar at Neurop, Inc.
Same institution · by research overlap
- George Walter Koszalka$3,138,178
- Robert Zaczek$2,835,948
- Mark S Washburn$100,000
- Kamalesh Ruppa$345,996
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsN-Methyl-D-Aspartate ReceptorsSiteReceptorBrainPropertyMedicalIschemiaAdverse EffectsExhibitsPlasmaTissuesCostLeadSocialN-MethylaspartateBrain TissueInnovationNeuroprotectionPharmaceutical ChemistryStrokeCharacteristicsDisabilityMonitor
Grant awards (15)
Use of Bioinformatics and Genetics to Identify a New Class of Drugs for Neurological Disease$425,269
R21 · FY2021 · AG · contact PI
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme$393,610
U44 · FY2015 · NS
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme$48,422
U44 · FY2015 · NS
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme$5,000
U44 · FY2015 · NS
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme$748,822
U44 · FY2014 · NS
NMDA Receptor Subtype Selective Modualtors as Alzheimer's Disease Therapeutics$219,338
R41 · FY2014 · AG · contact PI
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme$86,250
U44 · FY2014 · NS
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme$994,652
U44 · FY2013 · NS
Optimization of Novel NR2C and NR2D subunit-selective NMDA receptor potentiators$346,261
R43 · FY2013 · MH · contact PI
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme$931,527
U44 · FY2012 · NS
Optimization of Novel NR2C and NR2D subunit-selective NMDA receptor potentiators$345,731
R43 · FY2012 · MH · contact PI
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme$299,541
U44 · FY2011 · NS
pH-Sensitive Glutamate Receptor Inhibitors: Clinical Candidate Selection$637,385
R44 · FY2007 · NS · contact PI
Neuroprotection of pH Sensitive NMDAR Antagonists in Cardiopulmonary Bypass Surge$125,788
R43 · FY2007 · NS · contact PI
pH-Sensitive Glutamate Receptor Inhibitors: Clinical Candidate Selection$766,198
R44 · FY2006 · NS · contact PI